Antiatherosclerotic Effects of Small-Molecular-Weight Compounds Enhancing Endothelial Nitric-Oxide Synthase (eNOS) Expression and Preventing eNOS Uncoupling

• Published in: The Journal of pharmacology and experimental therapeutics 2008-05, Vol.325 (2), p.370-379
• Main Authors: Wohlfart, Paulus, Xu, Hui, Endlich, Alexandra, Habermeier, Alice, Closs, Ellen I, Hübschle, Thomas, Mang, Christian, Strobel, Hartmut, Suzuki, Teri, Kleinert, Hartmut, Förstermann, Ulrich, Ruetten, Hartmut, Li, Huige
• Format: Article
• Language: English
• Subjects: Animals; Aorta - drug effects; Aorta - metabolism; Aorta - pathology; Apolipoproteins E - genetics; Atherosclerosis - drug therapy; Atherosclerosis - metabolism; Atherosclerosis - pathology; Benzamides - therapeutic use; Benzodioxoles - therapeutic use; Cell Line; Endothelial Cells - drug effects; Endothelial Cells - metabolism; Humans; Indans - therapeutic use; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Molecular Weight; Nitric Oxide - metabolism; Nitric Oxide Synthase Type II - genetics; Nitric Oxide Synthase Type II - metabolism; Nitric Oxide Synthase Type III - genetics; Nitric Oxide Synthase Type III - metabolism; Protective Agents - therapeutic use; RNA, Messenger - metabolism
• ISSN: 0022-3565; 1521-0103
• DOI: 10.1124/jpet.107.128009

Many cardiovascular diseases are associated with reduced levels of bioactive nitric oxide (NO) and an uncoupling of oxygen reduction from NO synthesis in endothelial NO synthase (eNOS uncoupling). In human endothelial EA.hy 926 cells, two small-molecular-weight compounds with related structures, 4-fluoro- N -indan-2-yl-benzamide (CAS no. 291756-32-6; empirical formula C 16 H 14 FNO; AVE9488) and 2,2-difluoro-benzo[1,3]dioxole-5-carboxylic acid indan-2-ylamide (CAS no. 450348-85-3; empirical formula C 17 H 13 F 2 NO 3 ; AVE3085), enhanced eNOS promoter activity in a concentration-dependent manner; with the responsible cis -element localized within the proximal 263 base pairs of the promoter region. RNA interference-mediated knockdown of the transcription factor Sp1 significantly reduced the basal activity of eNOS promoter, but it did not prevent the transcription activation by the compounds. Enhanced transcription of eNOS by AVE9488 in primary human umbilical vein endothelial cells was associated with increased levels of eNOS mRNA and protein expression, as well as increased bradykinin-stimulated NO production. In both wild-type C57BL/6J mice and apolipoprotein E-knockout (apoE-KO) mice, treatment with AVE9488 resulted in enhanced vascular eNOS expression. In apoE-KO mice, but not in eNOS-knockout mice, treatment with AVE9488 reduced cuff-induced neointima formation. A 12-week treatment with AVE9488 or AVE3085 reduced atherosclerotic plaque formation in apoE-KO mice, but not in apoE/eNOS-double knockout mice. Aortas from apoE-KO mice showed a significant generation of reactive oxygen species. This was partly prevented by nitric-oxide inhibitor N ω -nitro- l -arginine methyl ester, indicating eNOS uncoupling. Treatment of mice with AVE9488 enhanced vascular content of the essential eNOS cofactor (6 R )-5,6,7,8-tetrahydro- l -biopterin and reversed eNOS uncoupling. The combination of an up-regulated eNOS expression and a reversal of eNOS uncoupling is probably responsible for the observed vasoprotective properties of this new type of compounds.